Publication:
STEM CELLS FOR TREATMENT OF CARDIOVASCULAR DISEASES: AN UMBRELLA REVIEW OF RANDOMIZED CONTROLLED TRIALS.

Simple item page
dc.contributor.authorDemurtas, Jacopo
dc.contributor.authorFanelli, Giuseppe Nicolò
dc.contributor.authorRomano, Simone Lorenzo
dc.contributor.authorSolari, Marco
dc.contributor.authorYang, Lin
dc.contributor.authorSoysal, Pınar
dc.contributor.authorSánchez, Guillermo F López
dc.contributor.authorGrabovac, Igor
dc.contributor.authorSmith, Lee
dc.contributor.authorZorzi, Alessandro
dc.contributor.authorLuchini, Claudio
dc.contributor.authorVeronese, Nicola
dc.contributor.institutionauthorSOYSAL, PINAR
dc.date.accessioned2021-01-13T20:59:07Z
dc.date.available2021-01-13T20:59:07Z
dc.date.issued2021-01-09T00:00:00Z
dc.description.abstractAIMS Stem cells are a promising therapy for various medical conditions. The literature regarding their adoption for the clinical care of cardiovascular diseases (CVD) is still conflicting. Therefore, our aim is to assess the strength and credibility of the evidence on clinical outcomes and application of stem cells derived from systematic reviews and meta-analyses of intervention studies in CVD. METHODS and RESULTS Umbrella review of systematic reviews with meta-analyses of randomized controlled trials (RCTs) using placebo/no intervention as control group. For meta-analyses of RCTs, outcomes with a random-effect p-value< 0.05, the GRADE (Grading of Recommendations Assessment, Development and Evaluation) assessment was used, classifying the evidence from very low to high. From 184 abstracts initially identified, 11 meta-analyses (for a total of 34 outcomes) were included. Half of the outcomes were statistically significant (p < 0.05), indicating that stem cells are more useful than placebo. High certainty of evidence supports the associations of the use of stem cells with a better left ventricular end systolic volume and left ventricular ejection fraction (LVEF) in acute myocardial infarction; improved exercise time in refractory angina; a significant lower risk of amputation rate in critical limb ischemia; a higher successful rate in complete healing in case of lower extremities ulcer; and better values of LVEF in systolic heart failure, as compared to placebo. CONCLUSION and RELEVANCE The adoption of stem cells in clinical practice is supported by a high certainty of strength in different CVD, with the highest strength in acute myocardial infarction and refractory angina.
dc.identifier.citationDemurtas J., Fanelli G. N. , Romano S. L. , Solari M., Yang L., Soysal P., Sánchez G. F. L. , Grabovac I., Smith L., Zorzi A., et al., -STEM CELLS FOR TREATMENT OF CARDIOVASCULAR DISEASES: AN UMBRELLA REVIEW OF RANDOMIZED CONTROLLED TRIALS.-, Ageing research reviews, ss.101257, 2021
dc.identifier.doi10.1016/j.arr.2021.101257
dc.identifier.pubmed33434684
dc.identifier.urihttp://hdl.handle.net/20.500.12645/27886
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1568163721000040?via%3Dihub
dc.subjectStem cell
dc.subjectCardiovascular diseases
dc.titleSTEM CELLS FOR TREATMENT OF CARDIOVASCULAR DISEASES: AN UMBRELLA REVIEW OF RANDOMIZED CONTROLLED TRIALS.
dc.typeArticle
dspace.entity.typePublication
local.avesis.ida1c48920-a3c3-4afa-8bd1-019942a72d87
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublication0e36986e-d71d-4579-a395-877af097ade5
relation.isAuthorOfPublication.latestForDiscovery0e36986e-d71d-4579-a395-877af097ade5
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
STEM CELLS FOR TREATMENT OF CARDIOVASCULAR DISEASES AN UMBRELLA REVIEW OF RANDOMIZED CONTROLLED TRIALS.pdf
Size:
2.31 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Yayınlar - Eserler